CCKAR and obesity disorder: Compound 1 was identified in a high-throughput screening project looking for small-molecule compounds that possess positive allosteric modulatory activity to enhance CCK action at the CCK1R, while possessing minimal endogenous agonist activity, a profile we have previously proposed for possible use in obesity to safely reduce appetite and lead to sustainable weight loss (7).